| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE)
RARE Technical Analysis
4
| As on 9th Jun 2023 RARE STOCK Price closed @ 51.38 and we RECOMMEND Sell for LONG-TERM with Stoploss of 57.87 & Strong Sell for SHORT-TERM with Stoploss of 72.41 we also expect STOCK to react on Following IMPORTANT LEVELS. |
RARESTOCK Price
| Open | 51.62 | Change | Price | % |
| High | 51.97 | 1 Day | -0.20 | -0.39 |
| Low | 51.00 | 1 Week | 2.02 | 4.09 |
| Close | 51.38 | 1 Month | 8.92 | 21.01 |
| Volume | 405400 | 1 Year | -36.48 | -41.52 |
| 52 Week High 87.86 | 52 Week Low 33.72 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| RARE Daily Charts |
RARE Intraday Charts |
Whats New @ Bazaartrend |
RARE Free Analysis |
|
|
RARE Important Levels Intraday
| RESISTANCE | 53.25 |
| RESISTANCE | 52.65 |
| RESISTANCE | 52.28 |
| RESISTANCE | 51.91 |
| SUPPORT | 50.85 |
| SUPPORT | 50.48 |
| SUPPORT | 50.11 |
| SUPPORT | 49.51 |
RARE Forecast May 2024
| 4th UP Forecast | 85.06 |
| 3rd UP Forecast | 74.26 |
| 2nd UP Forecast | 67.58 |
| 1st UP Forecast | 60.91 |
| 1st DOWN Forecast | 41.85 |
| 2nd DOWN Forecast | 35.18 |
| 3rd DOWN Forecast | 28.5 |
| 4th DOWN Forecast | 17.7 |
RARE Weekly Forecast
| 4th UP Forecast | 63.23 |
| 3rd UP Forecast | 59.43 |
| 2nd UP Forecast | 57.08 |
| 1st UP Forecast | 54.73 |
| 1st DOWN Forecast | 48.03 |
| 2nd DOWN Forecast | 45.68 |
| 3rd DOWN Forecast | 43.33 |
| 4th DOWN Forecast | 39.53 |
RARE Forecast2024
| 4th UP Forecast | 156.9 |
| 3rd UP Forecast | 123.06 |
| 2nd UP Forecast | 102.14 |
| 1st UP Forecast | 81.22 |
| 1st DOWN Forecast | 21.54 |
| 2nd DOWN Forecast | 0.62 |
| 3rd DOWN Forecast | -20.3 |
| 4th DOWN Forecast | -54.14 |
Ultragenyx Pharmaceutical Inc ( NASDAQ USA Symbol : RARE )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
RARE Business Profile
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; and Dojolvi for treating long-chain fatty acid oxidation disorders. The company is also developing DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California. Address: 60 Leveroni Court, Novato, CA, United States, 94949
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service